These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

542 related articles for article (PubMed ID: 26097600)

  • 1. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Han B; Guo Z; Ma Y; Kang S; Wang Y; Wei Q; Wu X
    Int J Clin Exp Pathol; 2015; 8(4):4113-9. PubMed ID: 26097600
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of GSTP1 Ile105Val and XRCC1 Arg194Trp, Arg280His and Arg399Gln gene polymorphisms in the clinical outcome of advanced non-small cell lung cancer.
    Zhao R; Chen G
    Int J Clin Exp Pathol; 2015; 8(11):14909-16. PubMed ID: 26823821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical outcome of cisplatin-based chemotherapy is associated with the polymorphisms of GSTP1 and XRCC1 in advanced non-small cell lung cancer patients.
    Deng JH; Deng J; Shi DH; Ouyang XN; Niu PG
    Clin Transl Oncol; 2015 Sep; 17(9):720-6. PubMed ID: 26033426
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of XRCC1 gene polymorphisms in non-small cell lung cancer cisplatin-based chemotherapy, and their effect on clinical and pathological characteristics.
    Liu HF; Liu JS; Deng JH; Wu RR
    Genet Mol Res; 2016 Dec; 15(4):. PubMed ID: 28081275
    [TBL] [Abstract][Full Text] [Related]  

  • 5. GSTP1 Ile105Val and XRCC1 Arg399Gln gene polymorphisms contribute to the clinical outcome of patients with advanced non-small cell lung cancer.
    Bu L; Zhang LB; Mao X; Wang P
    Genet Mol Res; 2016 Jun; 15(2):. PubMed ID: 27323109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of GSTP1 and XRCC1 gene polymorphisms with clinical outcomes of patients with advanced non-small cell lung cancer.
    Liu JY; Liu QM; Li LR
    Genet Mol Res; 2015 Aug; 14(3):10331-7. PubMed ID: 26345972
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic significance of GSTP1, XRCC1 and XRCC3 polymorphisms in non-small cell lung cancer patients.
    Ke HG; Li J; Shen Y; You QS; Yan Y; Dong HX; Liu JH; Shen ZY
    Asian Pac J Cancer Prev; 2012; 13(9):4413-6. PubMed ID: 23167352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of DNA base excision repair genes (OGG1, APE1 and XRCC1) polymorphisms with outcome to platinum-based chemotherapy in advanced nonsmall-cell lung cancer patients.
    Peng Y; Li Z; Zhang S; Xiong Y; Cun Y; Qian C; Li M; Ren T; Xia L; Cheng Y; Wang D
    Int J Cancer; 2014 Dec; 135(11):2687-96. PubMed ID: 24729390
    [TBL] [Abstract][Full Text] [Related]  

  • 9. DNA repair gene polymorphisms predict favorable clinical outcome in advanced non-small-cell lung cancer.
    Kalikaki A; Kanaki M; Vassalou H; Souglakos J; Voutsina A; Georgoulias V; Mavroudis D
    Clin Lung Cancer; 2009 Mar; 10(2):118-23. PubMed ID: 19362955
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of GSTs gene polymorphisms with treatment outcome of advanced non-small cell lung cancer patients with cisplatin-based chemotherapy.
    Wu G; Jiang B; Liu X; Shen Y; Yang S
    Int J Clin Exp Pathol; 2015; 8(10):13346-52. PubMed ID: 26722539
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of GSTM1, GSTT1, and GSTP1 IIe105Val gene polymorphisms in the response to chemotherapy and overall survival of advanced non-small cell lung cancer.
    Jia W; Sun JY; Jia KY; Liu XC
    Genet Mol Res; 2016 Sep; 15(3):. PubMed ID: 27706763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of polymorphisms in the XRCC1, XRCC3, and XPG genes on clinical outcomes of platinum-based chemotherapy for treatment of non-small cell lung cancer.
    Jin ZY; Zhao XT; Zhang LN; Wang Y; Yue WT; Xu SF
    Genet Mol Res; 2014 Mar; 13(3):7617-25. PubMed ID: 24737519
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
    Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
    Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
    Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
    Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
    [TBL] [Abstract][Full Text] [Related]  

  • 15. No association between XRCC1 polymorphisms and survival in non-small-cell lung cancer patients treated with platinum-based chemotherapy.
    Yuan P; Liu L; Wu C; Zhong R; Yu D; Wu J; Xu Y; Nie S; Miao X; Sun Y; Xu B; Lin D
    Cancer Biol Ther; 2010 Nov; 10(9):854-9. PubMed ID: 20814250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Glutathione-S-transferase P1 isoenzyme polymorphisms, platinum-based chemotherapy, and non-small cell lung cancer.
    Booton R; Ward T; Heighway J; Ashcroft L; Morris J; Thatcher N
    J Thorac Oncol; 2006 Sep; 1(7):679-83. PubMed ID: 17409936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assoication of XRCC1 gene polymorphisms with risk of non-small cell lung cancer.
    Kang S; Ma Y; Liu C; Cao C; Hanbateer ; Qi J; Li J; Wu X
    Int J Clin Exp Pathol; 2015; 8(4):4171-6. PubMed ID: 26097609
    [TBL] [Abstract][Full Text] [Related]  

  • 18. XRCC1 Arg399Gln and clinical outcome of platinum-based treatment for advanced non-small cell lung cancer: a meta-analysis in 17 studies.
    Chen J; Zhao QW; Shi GM; Wang LR
    J Zhejiang Univ Sci B; 2012 Nov; 13(11):875-83. PubMed ID: 23125080
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The codon 399 Arg/Gln XRCC1 polymorphism is associated with lung cancer in Indians.
    Natukula K; Jamil K; Pingali UR; Attili VS; Madireddy UR
    Asian Pac J Cancer Prev; 2013; 14(9):5275-9. PubMed ID: 24175813
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lack of influence of XRCC1 and XPD gene polymorphisms on outcome of platinum-based chemotherapy for advanced non small cell lung cancers.
    Yao CY; Huang XE; Li C; Shen HB; Shi MQ; Feng JF; Pan LX; Tang JH
    Asian Pac J Cancer Prev; 2009; 10(5):859-64. PubMed ID: 20104979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.